Adocia

Adocia is a clinical-stage biotechnology company focused on developing innovative formulations and delivery systems for metabolic diseases, primarily diabetes and obesity. The company's strategy is built on four proprietary technology platforms (BioChaperone®, AdoShell®, AdOral®, AdoXLong) designed to enhance the efficacy and delivery of peptides, proteins, and cell therapies. Key achievements include advancing a Phase 3 ultra-rapid insulin and securing partnerships with major pharmaceutical firms like Eli Lilly and Tonghua Dongbao. Adocia's business model involves licensing out its validated assets post-proof-of-concept to global partners for development and commercialization.

Adocia leverages four proprietary platforms: BioChaperone® for protein/peptide formulation, AdoShell® for immunoprotective cell therapy, AdOral® for oral delivery of peptides, and AdoXLong for long-acting peptides, all focused on improving treatments for diabetes and obesity.

Adocia competes directly with diabetes giants Novo Nordisk, Eli Lilly, and Sanofi in insulin and GLP-1 markets. Its ultra-rapid insulin faces off against Fiasp and Lyumjev, while its long-acting peptide platform enters a market dominated by semaglutide and tirzepatide. Its cell therapy program competes with other biotech encapsulation approaches.